Proteomic biomarkers of accelerated aging in multiple myeloma – clinical validation study

A2002540

Multiple Myeloma (MM), the second most common blood cancer, which predominantly affects older adults. Identifying frail individuals who may struggle with systemic therapy poses a significant challenge for clinicians. To address this, Professor Gordon Cook and the team have developed and are currently testing clinical scores aimed at pinpointing vulnerable patients. However, laboratory tests (biomarkers) are also essential to enhance the ability to identify these patients accurately.

In this national study, the team are evaluating the effectiveness of these scores in delivering personalised medicine to this patient group. The approach includes examining body fat and muscle through CT scanning and measuring blood markers of inflammation and fat tissue activity.

This project is a vital component of a broader program dedicated to defining patients' ability to tolerate treatment, ultimately aiming to improve outcomes for those affected by multiple myeloma.

Lead Researcher	Prof Gordon Cook Professor of Haematology & Fund Holder
Co-Researchers	Dr Claire Taylor BRC Haematology Research Fellow
Host Organisation/CSU	Oncology University of Leeds
Grant Amount	£9,588
Start Date	01/10/2023
Estimated Duration	5 months
Impact Areas	Health Inequalities – Cancer Care
Tags/key notes	Cancer and Neoplasms